Clinical trials · Tennessee
Pancreatic Adenocarcinoma clinical trials in Tennessee
We’re tracking 40 recruiting pancreatic adenocarcinoma studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Germantown, TennesseeAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Nashville, TennesseeAges 18 years+ - NCT07252232RecruitingPhase 3
A pill to prevent pancreatic cancer recurrence after surgery
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
Nashville, TennesseeAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Nashville, TennesseeAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Collierville, TennesseeAges 18 years+ - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Nashville, TennesseeAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Collierville, TennesseeAges 18 years+ - NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Nashville, TennesseeAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Collierville, TennesseeAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Nashville, TennesseeAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Nashville, TennesseeAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Nashville, TennesseeAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Nashville, TennesseeAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Nashville, TennesseeAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Nashville, TennesseeAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Nashville, TennesseeAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Nashville, TennesseeAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Nashville, TennesseeAges 18 years+ - NCT04970056Recruiting
Pancreatic cancer risk and early-detection registry study
This study builds a database of people at higher risk for pancreatic cancer (or certain early warning findings) to help find better ways to detect the disease early. You may be asked to complete health questionnaires and possibly donate a blood/saliva/swab sample.
Knoxville, TennesseeAges 18–90 - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Nashville, TennesseeAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Nashville, TennesseeAges 18 years+
Pancreatic Adenocarcinoma trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting pancreatic adenocarcinoma studies listed above.
- Vanderbilt University Medical Center · 6 studies
- Sarah Cannon Research Institute · 5 studies
- SCRI Oncology Partners · 5 studies
- Baptist Memorial Hospital and Cancer Center-Collierville · 3 studies
- Baptist Memorial Hospital and Cancer Center-Memphis · 3 studies
- Context Investigational Site
- Investigative Site US039
- Investigative Site US060
What taking part in a pancreatic adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pancreatic Adenocarcinoma trials in other states
Common questions
- Are there pancreatic adenocarcinoma clinical trials in Tennessee?
- Yes. We're currently tracking 40 recruiting pancreatic adenocarcinoma studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic adenocarcinoma study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic adenocarcinoma studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.